Table 5.
Phase III trials of molecularly targeted agents for advanced and metastatic pancreatic cancer
| Author | Chemo | Year | No. of patients | RR, % | PFS (mo) | OS (mo) | 1-year survival (%) |
|---|---|---|---|---|---|---|---|
| Bramhall et al141 | Marimastat | 2001 | 414 | 3 | 2.9 | 4 | 14–20 |
| GEM | 26 | 4.9 (P = 0.0001) | 5.6 (P = 0.19) | 19 | |||
| Bramhall et al142 | GEM | 2002 | 239 | 16 | 3.2 | 5.5 | 17 |
| GEM + marimastat | 11 | 3.1 (P = 0.68) | 5.4 (P = 0.95) | 18 | |||
| Moore et al143 | Talomastat | 2003 | 277 | 1 | 1.68 | 3.74 | 10 |
| GEM | 5 | 3.5 (P < 0.001) | 6.59 | 25 | |||
| Van Cutsem et al144 | GEM | 2007 | 688 | 8 | 3.6 (P = 0.72) | 6.1 | 24 |
| GEM + tafarnib | 6 | 3.7 | 6.4 (P = 0.75) | 27 | |||
| Philip93 S0205 | Cetuximab | 2007 | 7 | 3.5 | 6.5 | ||
| 7 | 3 (P = 0.058) | 6.0 (P = 0.14) | |||||
| Kindler et al96 CALGB 8030 | Bevacizumab | 2007 | 11 | 4.7 | 5.8 | ||
| 10 | 4.9 (P = 0.99) | 6.1 (P = 0.78) |
Abbreviations: RR, response rate; PFS, progression-free survival; OS, overall survival; GEM, gemcitabine.